102 related articles for article (PubMed ID: 19997880)
1. Detection of adriamycin-DNA adducts by accelerator mass spectrometry.
Coldwell K; Cutts SM; Ognibene TJ; Henderson PT; Phillips DR
Methods Mol Biol; 2010; 613():103-18. PubMed ID: 19997880
[TBL] [Abstract][Full Text] [Related]
2. Detection of Adriamycin-DNA adducts by accelerator mass spectrometry at clinically relevant Adriamycin concentrations.
Coldwell KE; Cutts SM; Ognibene TJ; Henderson PT; Phillips DR
Nucleic Acids Res; 2008 Sep; 36(16):e100. PubMed ID: 18632763
[TBL] [Abstract][Full Text] [Related]
3. The formation of AFB(1)-macromolecular adducts in rats and humans at dietary levels of exposure.
Cupid BC; Lightfoot TJ; Russell D; Gant SJ; Turner PC; Dingley KH; Curtis KD; Leveson SH; Turteltaub KW; Garner RC
Food Chem Toxicol; 2004 Apr; 42(4):559-69. PubMed ID: 15019179
[TBL] [Abstract][Full Text] [Related]
4. Accelerator mass spectrometry allows for cellular quantification of doxorubicin at femtomolar concentrations.
DeGregorio MW; Dingley KH; Wurz GT; Ubick E; Turteltaub KW
Cancer Chemother Pharmacol; 2006 Feb; 57(3):335-42. PubMed ID: 16047147
[TBL] [Abstract][Full Text] [Related]
5. Redox pathway leading to the alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin.
Taatjes DJ; Gaudiano G; Resing K; Koch TH
J Med Chem; 1997 Apr; 40(8):1276-86. PubMed ID: 9111302
[TBL] [Abstract][Full Text] [Related]
6. The power and potential of doxorubicin-DNA adducts.
Cutts SM; Nudelman A; Rephaeli A; Phillips DR
IUBMB Life; 2005 Feb; 57(2):73-81. PubMed ID: 16036566
[TBL] [Abstract][Full Text] [Related]
7. Characterization of oxaliplatin-DNA adduct formation in DNA and differentiation of cancer cell drug sensitivity at microdose concentrations.
Hah SS; Sumbad RA; de Vere White RW; Turteltaub KW; Henderson PT
Chem Res Toxicol; 2007 Dec; 20(12):1745-51. PubMed ID: 18001055
[TBL] [Abstract][Full Text] [Related]
8. The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity.
Swift LP; Cutts SM; Nudelman A; Levovich I; Rephaeli A; Phillips DR
Cancer Chemother Pharmacol; 2008 Apr; 61(5):739-49. PubMed ID: 17594094
[TBL] [Abstract][Full Text] [Related]
9. DNA adducts: mass spectrometry methods and future prospects.
Farmer PB; Brown K; Tompkins E; Emms VL; Jones DJ; Singh R; Phillips DH
Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):293-301. PubMed ID: 15990134
[TBL] [Abstract][Full Text] [Related]
10. Kinetics of carboplatin-DNA binding in genomic DNA and bladder cancer cells as determined by accelerator mass spectrometry.
Hah SS; Stivers KM; de Vere White RW; Henderson PT
Chem Res Toxicol; 2006 May; 19(5):622-6. PubMed ID: 16696564
[TBL] [Abstract][Full Text] [Related]
11. Quantification of tamoxifen DNA adducts using on-line sample preparation and HPLC-electrospray ionization tandem mass spectrometry.
Gamboa da Costa G; Marques MM; Beland FA; Freeman JP; Churchwell MI; Doerge DR
Chem Res Toxicol; 2003 Mar; 16(3):357-66. PubMed ID: 12641436
[TBL] [Abstract][Full Text] [Related]
12. Adduction of biomacromolecules with acrylamide (AA) in mice at environmental dose levels studied by accelerator mass spectrometry.
Xie Q; Sun H; Liu Y; Ding X; Fu D; Liu K
Toxicol Lett; 2006 May; 163(2):101-8. PubMed ID: 16280212
[TBL] [Abstract][Full Text] [Related]
13. Quantitative correlation of drug bioactivation and deoxyadenosine alkylation by acylfulvene.
Neels JF; Gong J; Yu X; Sturla SJ
Chem Res Toxicol; 2007 Oct; 20(10):1513-9. PubMed ID: 17900171
[TBL] [Abstract][Full Text] [Related]
14. The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells.
Poljaková J; Eckschlager T; Hrabeta J; Hrebacková J; Smutný S; Frei E; Martínek V; Kizek R; Stiborová M
Biochem Pharmacol; 2009 May; 77(9):1466-79. PubMed ID: 19426684
[TBL] [Abstract][Full Text] [Related]
15. Use of DNA adducts to identify human health risk from exposure to hazardous environmental pollutants: the increasing role of mass spectrometry in assessing biologically effective doses of genotoxic carcinogens.
Farmer PB; Singh R
Mutat Res; 2008; 659(1-2):68-76. PubMed ID: 18468947
[TBL] [Abstract][Full Text] [Related]
16. Sensitive quantitation of chromium-DNA adducts by inductively coupled plasma mass spectrometry with a direct injection high-efficiency nebulizer.
Singh J; McLean JA; Pritchard DE; Montaser A; Patierno SR
Toxicol Sci; 1998 Dec; 46(2):260-5. PubMed ID: 10048129
[TBL] [Abstract][Full Text] [Related]
17. Molecular basis for the synergistic interaction of adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9).
Cutts SM; Rephaeli A; Nudelman A; Hmelnitsky I; Phillips DR
Cancer Res; 2001 Nov; 61(22):8194-202. PubMed ID: 11719450
[TBL] [Abstract][Full Text] [Related]
18. DNA repair in response to anthracycline-DNA adducts: a role for both homologous recombination and nucleotide excision repair.
Spencer DM; Bilardi RA; Koch TH; Post GC; Nafie JW; Kimura K; Cutts SM; Phillips DR
Mutat Res; 2008 Feb; 638(1-2):110-21. PubMed ID: 17961607
[TBL] [Abstract][Full Text] [Related]
19. Depurinating acylfulvene-DNA adducts: characterizing cellular chemical reactions of a selective antitumor agent.
Gong J; Vaidyanathan VG; Yu X; Kensler TW; Peterson LA; Sturla SJ
J Am Chem Soc; 2007 Feb; 129(7):2101-11. PubMed ID: 17256933
[TBL] [Abstract][Full Text] [Related]
20. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R
Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
